 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer |
(Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Hospital Clínic i Provincial de Barcelona) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
| Data: | 2022 |
| Resum: | The mutational status of certain genes can be useful to advance therapeutic decision making and clinical management of cancer patients. In metastatic colorectal cancer, current clinicopathological factors employed in clinical practice have low or modest individual effect on survival, leading to a poor ability to discriminate patients at high risk. Here, we obtained data from metastatic colorectal cancer patients undergoing molecular testing by targeted gene sequencing, and we identified SMAD4 and FBXW7 mutated genes as negative prognostic markers in TP53 -driven tumors, which also improved the predictive performance to discriminate high-risk patients beyond clinical factors alone. This negative prognostic impact of co-occurring SMAD4 / TP53 and FBXW7 / TP53 mutations was confirmed in an independent validation analysis using publicly available data. Next-generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metastatic colorectal cancer (mCRC). Among a total of 294 mCRC tumors examined by targeted NGS, 200 of them derived from patients treated with first-line chemotherapy plus/minus monoclonal antibodies were included in prognostic analyses. Discriminative performance was assessed by time-dependent estimates of the area under the curve (AUC). The most recurrently mutated genes were TP53 (64%), KRAS or NRAS (49%), PIK3CA (15%), SMAD4 (14%), BRAF (13%), and FBXW7 (9. 5%). Mutations in FBXW7 correlated with worse OS rates (p = 0. 036; HR, 2. 24) independently of clinical factors. Concurrent mutations in TP53 and FBXW7 were associated with increased risk of death (p = 0. 02; HR, 3. 31) as well as double-mutated TP53 and SMAD4 (p = 0. 03; HR, 2. 91). Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes. Addition of the mutational status of these genes upon clinical factors resulted in a time-dependent AUC of 87%. Gene set enrichment analysis revealed specific molecular pathways associated with SMAD4 and FBXW7 mutations in TP53 -defficient tumors. Conclusively, SMAD4 and FBXW7 mutations in TP53 -altered tumors were predictive of a negative prognostic outcome in mCRC patients treated with first-line regimens. |
| Ajuts: | Instituto de Salud Carlos III CPII18/00026 Instituto de Salud Carlos III PI17/01304 Instituto de Salud Carlos III PI20/00863 Instituto de Salud Carlos III PI19/00740 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1035 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-001174 Instituto de Salud Carlos III FI18/00221 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Metastatic colorectal cancer ; Next-generation sequencing ; Mutational profiling ; Prognosis ; Left-sided colorectal cancer ; Machine learning |
| Publicat a: | Cancers, Vol. 14, Num. 23 (November 2022) , art. 5921, ISSN 2072-6694 |
